

Express Mail No.: **EV 473 971 651 US**

Sheet 1 of 1 of List of References

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-025-999	APPLICATION NO. 09/393,652
	APPLICANT Srivastava et al.	
	FILING DATE September 10, 1999	ART UNIT 1644

U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
<i>[Signature]</i>	CX	US 6,017,540	1/25/00	Srivastava	

FOREIGN PATENT DOCUMENTS						
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>[Signature]</i>	CY	BEN-YEHUDA et al., 2003, "Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents," Vaccine 21(23):3169-78
	CZ	MAZZAFERRO et al., 2003, "Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer," Clin. Cancer Res. 9(9):3235-45
	DA	SATO et al., 2001, "Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice," Blood 98(6):1852-7
	DB	TAMURA et al., 1997, "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations," Science 278(5335):117-20
	DC	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model," Int. J. Mol. Med. 4(3):243-8

EXAMINER NYI-3951160v1 <i>[Signature]</i> 4/26/07	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	